Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won. The immuno-oncology star trumped various chemo regimens at keeping cancer at bay in patients with advanced disease carrying specific biomarkers. More: Merck looks for leg up on
read moreIn the quest to treat COVID-19, chloroquine and hydroxychloroquine have drawn more attention than any other drugs. But while the FDA issued an emergency green light for their use against coronavirus, European regulators are limiting them strictly to clinical trials. More:
read moreBiocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time. The sign-off on the plant opens the way for a possible approval of the Lantus competitor developed with Mylan, which has been
read moreRoche Canada is looking for a few good ideas to fight COVID-19, and it needs them soon. Its recently launched Canada-specific innovation challenge has an April 10 deadline—and the promise of up to $100,000 to fund development. More: Roche Canada
read moreNovartis is still waiting for FDA guidance about what’s needed to lift the clinical hold on a trial testing a version of SMA gene therapy Zolgensma designed for older patients. That delay will push its launch back by a year,
read moreThe study will initially involve 15 sites across the UK More: Gilead starts late-stage trials in the UK of potential COVID-19 therapy Source: News
read more© 1994 - 2020 B.M. Pharmaceuticals